ALB and type 2 diabetes mellitus: Ertugliflozin, in addition to reducing the albumin/creatinine ratio in patients with type 2 diabetes and established diabetic nephropathy, also lowers the risk of kidney composite, which includes a significant decline in renal filtering capacity (doubling of serum creatinine or a sustained 40% decrease in eGFR), renal replacement therapy, and renal death [20-22].